Lindsay A. Rosenwald's most recent trade in Journey Medical Corp was a trade of 7,173 Common Stock, $0.0001 par value done . Disclosure was reported to the exchange on June 25, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Journey Medical Corp | Lindsay A. Rosenwald | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jun 2025 | 7,173 | 161,146 | - | 0 | Common Stock, $0.0001 par value | |
| Checkpoint Therapeutics Inc | Lindsay A. Rosenwald | Director | 28 May 2025 | 207,007 | 0 (0%) | 0% | - | COMMON STOCK | ||
| Checkpoint Therapeutics Inc | Lindsay A. Rosenwald | Director | Grant, award, or other acquisition of securities at price $ 1.29 per share. | 28 May 2025 | 50,000 | 207,007 (0%) | 0% | 1.3 | 64,500 | COMMON STOCK |
| Checkpoint Therapeutics Inc | Lindsay A. Rosenwald | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 May 2025 | 12,195 | 157,007 (0%) | 0% | 0 | COMMON STOCK | |
| Fortress Biotech Inc | Lindsay A. Rosenwald | Director, PRESIDENT, CEO & CHAIRMAN, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jan 2025 | 454,153 | 4,111,417 (5%) | 0% | 0 | Common stock, par value $0.001 | |
| Checkpoint Therapeutics Inc | Lindsay A. Rosenwald | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Dec 2024 | 12,638 | 144,812 (0%) | 0% | 0 | COMMON STOCK | |
| Fortress Biotech Inc | Lindsay A. Rosenwald | Director, PRESIDENT, CEO & CHAIRMAN, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 1.84 per share. | 23 Sep 2024 | 763,359 | 3,657,264 (5%) | 1% | 1.8 | 1,404,581 | Common stock, par value $0.001 |
| Fortress Biotech Inc | Lindsay A. Rosenwald | Director, PRESIDENT, CEO & CHAIRMAN, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 23 Sep 2024 | 763,359 | 763,359 | - | - | Warrants to Purchase Common Stock | |
| Avenue Therapeutics Inc | Lindsay A. Rosenwald | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Sep 2024 | 30,000 | 30,000 | - | - | Employee stock option (right to buy) | |
| Fortress Biotech Inc | Lindsay A. Rosenwald | Director, President, CEO & Chairman, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 7.48 per share. | 11 Jul 2024 | 5,000 | 127,500 | - | 7.5 | 37,418 | SERIES A CUMULATIVE PERPETUAL PREFERRED STOCK |
| Fortress Biotech Inc | Lindsay A. Rosenwald | Director, President, CEO & Chairman, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 7.39 per share. | 09 Jul 2024 | 5,000 | 122,500 | - | 7.4 | 36,971 | SERIES A CUMULATIVE PERPETUAL PREFERRED STOCK |
| Journey Medical Corp | Lindsay A. Rosenwald | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jul 2024 | 9,728 | 153,973 | - | 0 | Common Stock, $0.0001 par value | |
| Fortress Biotech Inc | Lindsay A. Rosenwald | Director, President, CEO & Chairman, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 7.35 per share. | 08 Jul 2024 | 5,000 | 117,500 | - | 7.4 | 36,765 | SERIES A CUMULATIVE PERPETUAL PREFERRED STOCK |
| Fortress Biotech Inc | Lindsay A. Rosenwald | Director, President, CEO & Chairman, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 1.64 per share. | 28 Jun 2024 | 20,000 | 2,893,905 (4%) | 0% | 1.6 | 32,724 | COMMON STOCK, PAR VALUE $0.001 |
| Fortress Biotech Inc | Lindsay A. Rosenwald | Director, President, CEO & Chairman, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 1.76 per share. | 16 May 2024 | 10,000 | 2,873,905 (4%) | 0% | 1.8 | 17,589 | COMMON STOCK, PAR VALUE $0.001 |
| Checkpoint Therapeutics Inc | Lindsay A. Rosenwald | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 May 2024 | 50,000 | 132,174 (0%) | 0% | 0 | COMMON STOCK | |
| Checkpoint Therapeutics Inc | Lindsay A. Rosenwald | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 May 2024 | 32,051 | 82,174 (0%) | 0% | 0 | COMMON STOCK | |
| Journey Medical Corp | Lindsay A. Rosenwald | Director | Purchase of securities on an exchange or from another person at price $ 3.04 per share. | 25 Mar 2024 | 10,000 | 144,245 | - | 3.0 | 30,400 | Common Stock, $0.0001 par value |
| Journey Medical Corp | Lindsay A. Rosenwald | Director | Purchase of securities on an exchange or from another person at price $ 3.40 per share. | 22 Mar 2024 | 20,000 | 134,245 | - | 3.4 | 68,000 | Common Stock, $0.0001 par value |
| Fortress Biotech Inc | Rosenwald Lindsay A. | Director, President, CEO & Chairman, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 2.38 per share. | 05 Jan 2024 | 50,000 | 2,863,905 (4%) | 0% | 2.4 | 118,770 | COMMON STOCK, PAR VALUE $0.001 |
| Fortress Biotech Inc | Rosenwald A. Lindsay | Director, President, CEO & Chairman, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jan 2024 | 216,465 | 2,813,905 (3%) | 0% | 0 | COMMON STOCK, PAR VALUE $0.001 | |
| Fortress Biotech Inc | Lindsay A. Rosenwald | Director, President, CEO & Chairman, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 11.75 per share. | 17 Aug 2023 | 10,000 | 102,500 | - | 11.8 | 117,500 | SERIES A CUMULATIVE PERPETUAL PREFERRED STOCK |
| Fortress Biotech Inc | Lindsay A. Rosenwald | Director, President, CEO & Chairman, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 9.34 per share. | 17 Aug 2023 | 10,000 | 112,500 | - | 9.3 | 93,400 | SERIES A CUMULATIVE PERPETUAL PREFERRED STOCK |
| Mustang Bio Inc | Lindsay A. Rosenwald | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jul 2023 | 7,246 | 60,525 (0%) | 0% | 0 | COMMON STOCK, PAR VALUE $0.0001 | |
| Avenue Therapeutics Inc | Lindsay A. Rosenwald | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2023 | 100,000 | 100,000 | - | - | Employee stock option (right to buy) | |
| Checkpoint Therapeutics Inc | Lindsay A. Rosenwald | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2023 | 17,483 | 50,123 (0%) | 0% | 0 | COMMON STOCK | |
| Fortress Biotech Inc | Lindsay A. Rosenwald | Director, President, CEO & Chairman, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 0.84 per share. | 10 Feb 2023 | 2,395,209 | 15,349,091 (21%) | 3% | 0.8 | 2,000,000 | COMMON STOCK, PAR VALUE $0.001 |
| Fortress Biotech Inc | Lindsay A. Rosenwald | Director, President, CEO & Chairman, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jan 2023 | 1,219,294 | 12,953,882 (18%) | 1% | 0 | COMMON STOCK, PAR VALUE $0.001 | |
| Fortress Biotech Inc | Lindsay A. Rosenwald | Director, President, CEO & Chairman, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.73 per share. | 01 Jan 2023 | 4,264 | 11,734,588 (16%) | 0% | 0.7 | 3,113 | COMMON STOCK, PAR VALUE $0.001 |
| Fortress Biotech Inc | Lindsay A. Rosenwald | Director, PRESIDENT, CEO & CHAIRMAN, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 0.68 per share. | 01 Dec 2022 | 100,000 | 11,730,324 (16%) | 0% | 0.7 | 67,960 | COMMON STOCK, PAR VALUE $0.001 |
| Fortress Biotech Inc | Lindsay A. Rosenwald | Director, PRESIDENT, CEO & CHAIRMAN, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 0.56 per share. | 30 Nov 2022 | 5,000 | 11,630,324 (16%) | 0% | 0.6 | 2,800 | COMMON STOCK, PAR VALUE $0.001 |
| Fortress Biotech Inc | Lindsay A. Rosenwald | Director, PRESIDENT, CEO & CHAIRMAN, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 0.70 per share. | 21 Oct 2022 | 100,000 | 11,625,324 (16%) | 0% | 0.7 | 69,500 | COMMON STOCK, PAR VALUE $0.001 |
| Journey Medical Corp | Lindsay A. Rosenwald | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jul 2022 | 14,245 | 14,245 | - | 0 | Common Stock, par value $0.0001 per share | |
| Mustang Bio Inc | Lindsay A. Rosenwald | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Mar 2022 | 71,664 | 294,181 (0%) | 0% | 0 | COMMON STOCK, PAR VALUE $0.0001 | |
| Mustang Bio Inc | Lindsay A. Rosenwald | Director | Purchase of securities on an exchange or from another person at price $ 0.52 per share. | 18 Mar 2022 | 5,000 | 299,181 (0%) | 0% | 0.5 | 2,582 | COMMON STOCK, PAR VALUE $0.0001 |
| Mustang Bio Inc | Lindsay A. Rosenwald | Director | Purchase of securities on an exchange or from another person at price $ 0.74 per share. | 18 Mar 2022 | 4,094 | 222,517 (0%) | 0% | 0.7 | 3,025 | COMMON STOCK, PAR VALUE $0.0001 |
| Mustang Bio Inc | Lindsay A. Rosenwald | Director | Grant, award, or other acquisition of securities at price $ 2.58 per share. | 31 Aug 2021 | 1,170 | 218,423 (0%) | 0% | 2.6 | 3,019 | COMMON STOCK |
| Mustang Bio Inc | Lindsay A. Rosenwald | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Jun 2021 | 13,774 | 217,253 (0%) | 0% | 0 | COMMON STOCK | |
| Mustang Bio Inc | Lindsay A. Rosenwald | Director | Grant, award, or other acquisition of securities at price $ 2.83 per share. | 26 Feb 2021 | 1,043 | 203,479 (0%) | 0% | 2.8 | 2,952 | COMMON STOCK |
| Mustang Bio Inc | Lindsay A. Rosenwald | Director | Purchase of securities on an exchange or from another person at price $ 2.66 per share. | 31 Aug 2020 | 100,000 | 202,436 (0%) | 0% | 2.7 | 266,000 | COMMON STOCK |
| Mustang Bio Inc | Lindsay A. Rosenwald | Director | Grant, award, or other acquisition of securities at price $ 2.48 per share. | 31 Aug 2020 | 1,182 | 102,436 (0%) | 0% | 2.5 | 2,931 | COMMON STOCK |
| Fortress Biotech Inc | Lindsay A. Rosenwald | Director, PRESIDENT, CEO & CHAIRMAN, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 18.00 per share. | 26 Aug 2020 | 52,500 | 92,500 | - | 18 | 945,000 | SERIES A CUMULATIVE PERPETUAL PREFERRED STOCK |